21573-10-4Relevant articles and documents
Cyclopropyl acetone and synthesis method thereof
-
Paragraph 0030-0031; 0033-0038; 0040-0044; 0046-0050; 0052, (2018/12/13)
The invention discloses cyclopropyl acetone and a synthesis method thereof. The synthesis method comprises the following steps: adding sodium into anhydrous ethanol while stirring, cooling the mixture, generating reaction, and recycling ethanol to obtain a mixed solution; adding cyclopropyl acetone into the mixed solution, stirring the cyclopropyl acetone and the mixed solution, adding ethyl acetate which is 1/3 of the mass, generating reflux reaction, and recycling ethanol; then cooling the product, adding ethyl acetate which is 1/3 of the mass, generating reflux reaction, and recycling ethanol; cooling the product again, adding ethyl acetate which is 1/3 of the mass, generating reflux reaction, recycling ethanol and the ethyl acetate at negative pressure, and storing the product at reduced temperature, thus obtaining a cyclopropyl acetone sodium salt solution; adjusting the pH of the cyclopropyl acetone sodium salt solution to be 2 to 3, stirring the solution, standing still the solution, taking upper brown red liquid for fractionation, and obtaining the cyclopropyl acetone. The content of the obtained cyclopropyl acetone is about 90 percent, and the yield is more than 90 percent; the synthesis method is mild in reaction conditions, high in catalysis efficiency, low in energy consumption, low in cost, high in safety and suitable for large-scale production of an enterprise, and the product is easy to recycle.
METHOD OF TREATMENT
-
Paragraph 0745, (2014/09/29)
The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.
New CRTh2 antagonists.
-
Paragraph 0179, (2013/03/26)
The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.